Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-06-15T08:37:17.097Z Has data issue: false hasContentIssue false

P03-334 - Neuroleptic Malignant Syndrome Diagnosis: an International Consensus Study Using the Delphi Technique

Published online by Cambridge University Press:  17 April 2020

R. Gurrera
Affiliation:
Harvard University Medical School, USA VA Boston Healthcare System, Brockton, MA, USA
S. Caroff
Affiliation:
University of Pennsylvania School of Medicine, Philadelphia, USA Philadelphia VA Medical Center, Phildelphia, USA
A. Cohen
Affiliation:
University of Pennsylvania School of Medicine, Philadelphia, USA Center for Clinical Epidemiology and Biostatistics, Philadelphia, PA, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

To develop consensus-based clinical diagnostic criteria for neuroleptic malignant syndrome (NMS).

Methods

A 17-member international expert panel of psychiatrists, neurologists, anesthesiologists and emergency medicine specialists was asked to identify clinical features that are most important or valuable in diagnosing NMS; when the feature was quantitative in nature, they were also asked to provide the corresponding critical value. The Delphi technique is a formal consensus procedure that employs a postal survey method to solicit opinions from each panel member, and to feed this information back to the entire panel in the form of anonymous, statistically aggregated data. This iterative process of information exchanges (opinions collected, group responses analyzed, feedback given to panel), or “rounds”, continues until consensus has been reached. In the present study, the predetermined consensus criterion was a round-round mean change of 10% or less for any survey item, and 5% or less across all items.

Results

The expert panel reached consensus on the following diagnostic criteria in five iterations:

  1. (1) exposure to a dopamine antagonist, or dopamine agonist withdrawal, within past 72 hours;

  2. (2) hyperthermia;

  3. (3) rigidity;

  4. (4) mental status alteration;

  5. (5) creatine phosphokinase elevation;

  6. (6) sympathetic nervous system lability (2 or more of blood pressure elevation, blood pressure fluctuation, diaphoresis, urinary incontinence);

  7. (7) tachycardia and tachypnea; and

  8. (8) negative work-up for infectious, toxic, metabolic and neurological causes.

Conclusions

These are the first consensus-based diagnostic criteria for NMS, and may be preferred to previous ad hoc approaches to diagnosing this disorder.

Type
Psychopharmacological treatment and biological therapies
Copyright
Copyright © European Psychiatric Association 2010
Submit a response

Comments

No Comments have been published for this article.